193
Participants
Start Date
August 31, 2014
Primary Completion Date
April 27, 2022
Study Completion Date
April 27, 2022
MGCD516
MGCD516 is a small molecule inhibitor of several closely related receptor tyrosine kinases. MGCD516 capsules will be taken with water.
Columbia University, New York
Montefiore Medical Center, The Bronx
Roswell Park Cancer Institute, Buffalo
Guthrie Clinical Research, Sayre
Maryland Oncology Hematology,, Rockville
Virginia Cancer Specialists, Fairfax
Oncology and Hematology Associates of Southwest Virginia, Inc., Blue Ridge Cancer Care, Roanoke
St. Francis Cancer Center, Greenville
Holy Cross Michael & Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale
Florida Cancer Specialists, Sarasota
Florida Cancer Affiliates, Ocala
University of Alabama, Birmingham
Sarah Cannon Research Institute, Nashville
Oncology Hematology Care, Inc., Cincinnati
University of Michigan, Ann Arbor
Henry Ford Health System, Detroit
University of Wisconsin, Madison
Northwestern University, Chicago
Rush University Medical Center, Chicago
Washington University Center for Advanced Medicine, St Louis
Oncology Hematology West PC, Nebraska Cancer Specialists, Omaha
CHI Health St Francis, Saint Francis Cancer Treatment Center, Grand Island
Ochsner Clinic Foundation, New Orleans
Mary Crowley Cancer Research Center, Dallas
Texas Oncology-Tyler, Tyler
University of Texas, MD Anderson Cancer Center, Houston
Texas Oncology-Austin Midtown, Austin
Rocky Mountain Cancer Center, Denver
The Huntsman Cancer Institute, Salt Lake City
University of New Mexico Cancer Research and Treatment Center, Albuquerque
Sarcoma Oncology Research Center, Santa Monica
Innovative Clinical Research Institute, Whittier
University of California, San Diego, San Diego
University of California, San Francisco, San Francisco
Seattle Cancer Care Alliance, Seattle
Northwest Cancer Specialists, P.C., Vancouver
Massachusetts General Hospital, Boston
Chungbuk National University Hospital, Cheongju-si
Keimyung University Dongsan Hospital, Daegu
National Cancer Center, Goyang-si
Korea Veterans Health Service, Seoul
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University Health System, Seoul
Lead Sponsor
Mirati Therapeutics Inc.
INDUSTRY